Abstract
The relationship between interleukin-6 and C-reactive protein was evaluated in patients with benign (n=59) and malignant (n=86) prostate disease. The correlation coefficients for patients with benign prostatic disease and prostate cancer were rs=0.632, P<0.001 and rs=0.663, P<0.001, respectively. These results indicate that the relationship between interleukin-6 and C-reactive protein is similar in patients with benign and malignant prostate disease.
Highlights
A number of factors appear to mediate the increased production of C-reactive protein
There were no significant differences in circulating concentrations of interleukin-6 and C-reactive protein between patients with benign disease and prostate cancer
There were no significant differences in the circulating concentrations of either interleukin-6 or C-reactive protein between patients with benign prostatic disease and those with prostate cancer
Summary
A number of factors appear to mediate the increased production of C-reactive protein. The pro-inflammatory cytokines, interleukin-1, TNF-alpha and interleukin-6 in particular, have been shown to stimulate the production of C-reactive protein (Gabay and Kushner, 1999). The factors which determine circulating concentrations of C-reactive protein are less clear, since studies in cell lines and animal tumour models have demonstrated that a number of factors stimulate C-reactive protein production. If in cancer patients Creactive protein was stimulated by factors other than interleukin-6, it might be expected that the relationship between interleukin-6 and C-reactive protein would be less strong than that in patients with benign disease. The aim of the present study was to examine the relationship between interleukin-6 and C-reactive protein in patients with benign disease (BPH) and in prostate cancer. No patient had a digital rectal examination within a 2-week period prior to sampling. Gleason scores were compressed as recommended previously (Bostwick et al, 2000)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
